However, a statistically significant percentage ranging from 67% in DCIS to 73% in TNBC and ER+/PR+/HER2- tumors expressed 2.4–4.9-fold higher levels of serum PLAC1 than control subjects. This evidence concerns the gene ERBB2 and ductal breast carcinoma in situ.